arrow
R

Renato Zambello

padua university school of medicine
H指数:59
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study

持续缓解(ORR4)作为莫加木单抗治疗蕈样真菌病和塞扎里综合征期间的治疗性预后标志物:FIL-MOGA研究

2026-09-210
OAAI
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy

多发性骨髓瘤患者在来那度胺维持治疗后进展的挽救治疗模式:欧洲骨髓瘤网络(EMN)意大利的真实世界研究

2026-09-050
OAAI
Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus

优化三药类暴露复发/难治性多发性骨髓瘤患者中BCMA靶向T细胞结合疗法的实际应用:一项意大利改良德尔菲共识

Cancers
IF4.4
2026-08-110
OA
Gene Expression, Non-Coding RNA, and Circular RNA Alterations in Patients with T-Prolymphocytic Leukemia

T-原淋巴细胞白血病患者中的基因表达、非编码RNA和环状RNA改变

Cancers
IF4.4
2026-07-300
OA
Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies

解决复发/难治性多发性骨髓瘤中的未满足需求:意大利德尔菲共识关于当前挑战和新兴疗法

2026-04-170
OAAI
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide

一项关于达拉妥单抗-硼替佐米-地塞米松(DaraVd)作为二线治疗方案的多中心观察性回顾性研究,用于对来那度胺耐药的多发性骨髓瘤患者。

2025-11-250
OAAI
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy

更正:连续或固定剂量卡非佐米、来那度胺和地塞米松(KRD)用于复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络(EMN)意大利多中心回顾性真实世界调查的长期随访结果

2025-11-130
OAAI
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework

支持意大利多发性骨髓瘤患者在DRd治疗后进行治疗的决策制定:一个多准则决策框架

2025-11-020
OAAI
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy

连续或固定剂量卡非佐米、来那度胺和地塞米松 (KRd) 治疗复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络 (EMN) 意大利 多中心、回顾性真实世界研究的长-term随访

2025-10-070
OA
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168

更正:Mancuso等人,《Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma》,《Cancers》2025年第17卷第1168页。

2025-08-200
PRE
Transcriptomic landscape of CD8+ and CD4 + T-LGL leukemia revealed the distinct impact of STAT3 and STAT5B activating mutations

CD8+和CD4+ T-LGL白血病的转录组景观揭示了STAT3和STAT5B激活突变的独特影响

Leukemia
IF13.4
2025-07-280
OA
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy

临床医生对荧光原位杂交技术(FISH)定义多发性骨髓瘤细胞遗传学风险的观点与方法学应用:欧洲骨髓瘤网络(EMN)意大利分会基于真实世界调查的报告

2025-03-290
OAAI
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients

daratumumab难治性多发性骨髓瘤的结局和预后指标: 埃洛妥珠单抗,波马利多明和地塞米松在247患者中的多中心真实世界研究

2025-02-011
PRE
Predictors of Splenectomy Response in Immune Thrombocytopenia: A Multicentric Italian Study
2024-12-250
OAAI
Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

激活STAT3突变驱动CD38在T-大颗粒淋巴细胞白血病中的表达

BLOOD
IF23.1
2024-11-050
PRE
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials
2024-05-314
PRE